Avtor/Urednik		Kraut, Aleksandra; Sevšek, Davorin; Jaki-Mekjavić, Polona; Urbančič, Mojca
Naslov		Kombinirano zdravljenje neovaskularne oblike starostne degeneracije makule s fotodinamičnim zdravljenjem in ranibizumabom - 2 letno poročilo
Prevedeni naslov		Combination therapy for neovascular form of agerelated macular degeneration with photodynamic therapy and ranizumab - 2 year report
Tip		članek
Vir		Zdrav Vestn
Vol. in št.		Letnik 79, št. Suppl
Leto izdaje		2010
Obseg		str. I-39-45
Jezik		slo
Abstrakt		Background: Evaluate the efficacy and safety of photodynamic therapy (PDT) combined with intravitreal injections of ranibizumab in choroidal neovascularisation (CNV) secondary to agerelated macular degeneration (AMD). Methods: Prospective, noncomparative, interventional case series of 10 patients. Patients were treated at baseline with verteporfin PDT, followed by intravitreal injection of 0.3mg ranibizumab one hour later. Repeated monthly ranibizumab injections were given for three months, followed by further monthly doses, if necessary, depending on the findings of the best corrected visual acuity (BCVA), and fluorescein angiography (FA). FA was conducted after 3, 6 and 12 months, and optical coherent tomography (OCT) in the last 18 months of the study. Efficacy was evaluated by the changes in BCVA using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, by anatomic outcomes on FA, and by number of retreatments. Safety was assessed by ophthalmic examinations, monitoring adverse events and vital signs. Results: Baseline BVCA ranged from 34-71 letters (mean 57.2). FA types CNV appeared as predominantly classic in 2, minimally classic in 3, occult without classic in 5 patients. Retinochoroidal anastomosis (RCA) was found in 4 patients. After one and two years mean BVCA was 70 and 66.4; mean gain was 12.8 and 9.2 letters respectively. FA outcomes after 6 months showed that all leasions were smaller, with CNV shrinkage while RCA disappeared. The number of ranibizumab injections per patient was 4-9 in year one and 0-5 in year two. There were no serious side effects. Conclusions: PDT combined with ranibizumab injections is a safe, effective, and appropriate therapy for neovascular forms of ARMD. Anatomic and visual outcomes are good and less retreatments are needed. Definitive significance of the therapy will be known after conclusion of ongoing large multicentric clinical trials.
Deskriptorji		MACULAR DEGENERATION FLUORESCEIN ANGIOGRAPHY VISUAL ACUITY ANTIBODIES, MONOCLONAL PHOTOCHEMOTHERAPY ENDOTHELIAL GROWTH FACTORS TREATMENT OUTCOME